Bortezomib in kidney transplantation

Current Opinion in Organ Transplantation

Volumn 20, Issue 6, 2015, Pages 652-656

  Shah, Neil ^a   Meouchy, Joseph ^b   Qazi, Yasir ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Department of Medicine   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bortezomib; Desensitization; Kidney transplant

Indexed keywords

BORTEZOMIB; IMMUNOSUPPRESSIVE AGENT; MORE; RITUXIMAB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

DRUG EFFICACY; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; REVIEW; ANIMAL; GRAFT REJECTION; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; BORTEZOMIB; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84947125878     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000252     Document Type: Review

References (11)

1. Miller SC, Huang R, Sakamuru S, et al. Identification of known drugs that acts as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem Pharmacol 2010; 79:1272-1280.
2. Blanco B, Pérez-Simon JA, Sanchez-Abarca LI, et al. Treatment with borte-zomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T cell population. Haematologica 2009; 94:975-983.
3. Lemy A, Toungouz M, Abramowicz D. Bortezomib: a new player in pre and posttransplant desensitization? Nephrol Dial Transplant 2010; 25:3480-3489.
4. Ejaz NS, Shields AR, Alloway RR, et al. Randomized controlled pilot study of B cell-targeted induction therapy in HLA sensitized kidney transplant recipients. Am J Transplant 2013; 13:3142-3154.
5. Woodle ES, Shields AR, Ejaz NS, et al. Prospective iterative trial of protea-some inhibitor-based desensitization. Am J Transplant 2015; 15:101-118.
6. Philogene MC, Sikorski P, Montgomery RA, et al. Differential effect of borte-zomibon HLA class I and class II antibody. Transplantation 2014;98:660-665.
7. Gupta G, Abu Jawdeh BG, Racusen LC, et al. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies. Transplantation 2014; 97:1240-1246.
8. Cicora F, Paz M, Mos F, Roberti J. Use of bortezomib to treat anti-HLA antibodies in renal transplant patients: a single-center experience. Transpl Immunol 2013; 29:7-10.
9. Nguyen S, Gallay B, Butani L. Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen. Pediatr Transplant 2014; 18:463-468.
10. Yang KS, Jeon H, Park Y, et al. Use of bortezomib as antihumoral therapy in kidney transplantation. J Korean Med Sci 2014; 29:648-651.
11. Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89:277-284.